Clinical trial
Phase II Iressa + Irradiation Followed by Chemo in NSCLC
NCT00333294 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00333294 |
|---|---|
| Title | Phase II Iressa + Irradiation Followed by Chemo in NSCLC |
| Official title | A Phase II Open-Label Multicentre Study Of The Efficacy Of ZD1839 (IRESSA™) In Combination With Irradiation Followed By Chemotherapy In Patients With Inoperable Stage III Non Small Cell Lung Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug, Procedure |
| Interventions | Gefitinib, Radiation therapy, Cisplatin, Vinorelbine |
| Enrollment | 50 |
| Start date | Sep 1, 2004 |
| Completion | Jan 1, 2006 |
| First posted | Jun 5, 2006 |
| Last update posted | Dec 19, 2007 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: